ReviewNature reviews. Drug discovery2006
Antiviral agents active against influenza A viruses.
Review in Nature reviews. Drug discovery, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 248 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
248 citing papers in PubMed, 665 citations in OpenAlex.
- Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases.BMC infectious diseases · 2023Trial
- Trial
- A functional genomics-pharmacotranscriptomics framework identifies host-directed anti-influenza agents.iScience · 2026Article
- Recent advances in adamantane-linked heterocycles: synthesis and biological activity.Molecular diversity · 2026Review
- Update on Influenza.The American journal of the medical sciences · 2026Review
- A scoping review of influenza RdRp-targeting inhibitors: mechanisms, clinical translation, and emerging challenges.Frontiers in microbiology · 2026Review
- Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026Review
- Epidemiology, evolution, and biological characteristics of H3 avian influenza viruses isolated from chickens in China.One health (Amsterdam, Netherlands) · 2025Article
- Bioluminescent reporter influenza A viruses to track viral infections.Microbiology spectrum · 2025Article
- Machine Learning Integration of Bulk and Single-Cell RNA-Seq Data Reveals Cathepsin B as a Central PANoptosis Regulator in Influenza.International journal of molecular sciences · 2025Article
- Licoflavone B Suppresses Influenza A Virus by Targeting the Viral RNA-Dependent RNA Polymerase (RdRp).Viruses · 2025Article
- Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals.npj antimicrobials and resistance · 2025Review
- A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Unfurling the Potential of Antiviral Agents Aimed for RNA Virus Ailment.Current drug targets · 2025Review
- Identification of Natural Terpenoid Compounds as Potential Inhibitors of Nucleoprotein of Influenza A Virus usingMedicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- Indole-core inhibitors of influenza a neuraminidase: iterative medicinal chemistry and molecular modeling.European journal of medicinal chemistry · 2024Article
- Article
- Phytochemical profiling, antiviral activities, molecular docking, and dynamic simulations of selected Ruellia species extracts.Scientific reports · 2024Article
- Natural Product-Derived Phytochemicals for Influenza A Virus (H1N1) Prevention and Treatment.Molecules (Basel, Switzerland) · 2024Review
- Miz1 represses type I interferon production and limits viral clearance during influenza A virus infection.Science signaling · 2024Article
188 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreaks of avian influenza A (H5N1) virus, its expanding geographic distribution and its ability to transfer to humans and cause severe infection have raised serious concerns about the measures available to control an avian or human pandemic of influenza A. In anticipation of such a pandemic, several preventive and therapeutic strategies have been proposed, including the stockpiling of antiviral drugs, in particular the neuraminidase inhibitors oseltamivir (Tamiflu; Roche) and zanamivir (Relenza; GlaxoSmithKline). This article reviews agents that have been shown to have activity against influenza A viruses and discusses their therapeutic potential, and also describes emerging strategies for targeting these viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.